PDIGREE: New Insights on Tolerability, Treatment Response of 1L Ipi/Nivo for mccRCC
PDIGREE: New Insights on Tolerability, Treatment Response of 1L Ipi/Nivo for mccRCC

Tian Zhang, MD, UT Southwestern Medical Center, gives an update on the PDIGREE trial, including new information on tolerability and treatment response to first-line ipi/nivo for patients with metastatic clear cell renal cell carcinoma.

She comments on differential clinical or radiographic response patterns that might inform early identification of non-responders, as well as how she sees this trial informing treatment decisions in intermediate- or poor-risk patients.

Advertisement

Latest News

Mitomycin Formulation is First-Ever FDA-Approved Treatment for Low-Grade, Intermediate-Risk, NMIBC
Mitomycin Formulation is First-Ever FDA-Approved Treatment for Low-Grade, Intermediate-Risk, NMIBC
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | June 12, 2025
The study’s major efficacy outcomes included a complete response in 78% of patients.
Ipilimumab Plus Nivolumab Outperforms SOC in OS Rates for Patients With nccRCC
Ipilimumab Plus Nivolumab Outperforms SOC in OS Rates for Patients With nccRCC
Emily MenendeznccRCC | June 12, 2025
At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
ASCO Annual Meeting Recap: Prostate Cancer
ASCO Annual Meeting Recap: Prostate Cancer
Karine Tawagi, MDProstate Cancer | June 12, 2025
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
ASCO Annual Meeting Recap: Kidney Cancer
ASCO Annual Meeting Recap: Kidney Cancer
Karine Tawagi, MDRenal Cell Carcinoma | June 12, 2025
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
ASCO Annual Meeting Recap: Bladder Cancer
ASCO Annual Meeting Recap: Bladder Cancer
Karine Tawagi, MDUrothelial Carcinoma | June 12, 2025
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Characterization of Circulating KIM-1: Understanding the Correlation With Protein Levels and Tumor Biology in Metastatic RCC
Characterization of Circulating KIM-1: Understanding the Correlation With Protein Levels and Tumor Biology in Metastatic RCC
Marc Machaalani, MDRenal Cell Carcinoma Diagnostics | June 11, 2025
Dr. Machaalani highlights his study that evaluated the association between circulating KIM-1 and mRCC tumor biology.
Utilizing AI to Determine ARPI Benefit for Non-Metastatic Prostate Cancer in the STAMPEDE Trial
Utilizing AI to Determine ARPI Benefit for Non-Metastatic Prostate Cancer in the STAMPEDE Trial
Nicholas James, PhDLocalized | June 9, 2025
Dr. James showcases an MMAI model to identify benefit from 2nd-generation ARPIs in hr/nm PCa patients from STAMPEDE.
SURE-02: Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab, Response-Adapted Bladder Sparing, and Adjuvant Pembrolizumab for Patients With MIBC
SURE-02: Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab, Response-Adapted Bladder Sparing, and Adjuvant Pembrolizumab for Patients With MIBC
Andrea Necchi, MDMuscle Invasive Urothelial Carcinoma | June 9, 2025
Drs. Necchi and Tawagi break down in detail the first results of SURE-02 in patients with muscle-invasive bladder cancer.
AMPLITUDE Demonstrates Extended Radiographic PFS With Addition of Niraparib to Abiraterone in HRR-altered mCSPC
AMPLITUDE Demonstrates Extended Radiographic PFS With Addition of Niraparib to Abiraterone in HRR-altered mCSPC
Lauren Dembeck, PhDmCSPC | June 9, 2025
Adding niraparib to abiraterone and prednisone prolongs rPFS in patients with mCSPC harboring HRR gene alterations.
CLONEVO: Preoperative Abemaciclib for Cisplatin-Ineligible MIBC With Molecular Response Assessment
CLONEVO: Preoperative Abemaciclib for Cisplatin-Ineligible MIBC With Molecular Response Assessment
Bishoy Faltas, MDMuscle Invasive Urothelial Carcinoma | June 6, 2025
Dr. Faltas highlights CLONEVO, a trial using preoperative abemaciclib in cisplatin-ineligible MIBC with ctDNA monitoring.
Efficacy, Safety of Mitomycin Plus BCG for Patients With High-Risk Non-Muscle Invasive Bladder Cancer
Efficacy, Safety of Mitomycin Plus BCG for Patients With High-Risk Non-Muscle Invasive Bladder Cancer
Dickon Hayne, MDNon-Muscle Invasive Urothelial Carcinoma | June 6, 2025
Dr. Hayne speaks about the ANZUP 101 trial results that evaluated the combination of mitomycin and BCG for NMIBC.
Prognostic Significance of PSA>0.2 After 6-12 Months of Treatment for mHSPC Intensified by ARPI: A Real-World Analysis
Prognostic Significance of PSA>0.2 After 6-12 Months of Treatment for mHSPC Intensified by ARPI: A Real-World Analysis
Michael Ong, MDmCSPC | June 6, 2025
Drs. Ong and Roy detail a multinational real-world analysis of the IRONMAN registry on the significance of PSA>0.2.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Katy Beckermann, MD, PhD
Katy Beckermann, MD, PhDEditor | Medical Director of GU Clinical Research at Tennessee Oncology
Christopher Wallis, MD, PhD, FRCSC
Christopher Wallis, MD, PhD, FRCSCAssistant Professor of Urology | University of Toronto
Akhil Abraham Saji, MD
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MD
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024
The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Teaching TURBT Over 5G: Integrating XR Headsets Into Urologic Practice
Teaching TURBT Over 5G: Integrating XR Headsets Into Urologic Practice
Evan Kovac, MDProstate Cancer | May 19, 2025
Dr. Evan Kovac speaks about his pioneering work with extended reality display technology in urologic surgery and education.
Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy
Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy
Alexandre Zlotta, MDMuscle Invasive Urothelial Carcinoma | May 15, 2025
Dr. Zlotta discusses the current state and future of bladder-sparing therapy in MIBC, including how to best select patients.
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
James “Jim” Brugarolas, MD, PhDRenal Cell Carcinoma | April 22, 2025
Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | March 17, 2025
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Akhil Abraham Saji, MDLocalized | January 14, 2025
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
David Ambinder, MDLocalized | January 6, 2025
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.

Conference Coverage

Live meeting highlights

Ipilimumab Plus Nivolumab Outperforms SOC in OS Rates for Patients With nccRCC
Emily MenendeznccRCC | June 12, 2025
At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
Read More
ASCO Annual Meeting Recap: Prostate Cancer
Karine Tawagi, MDProstate Cancer | June 12, 2025
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
View More
ASCO Annual Meeting Recap: Kidney Cancer
Karine Tawagi, MDRenal Cell Carcinoma | June 12, 2025
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
View More
ASCO Annual Meeting Recap: Bladder Cancer
Karine Tawagi, MDUrothelial Carcinoma | June 12, 2025
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
View More

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and research relevant to their patients and practices. Featuring the latest clinical updates from all facets of the specialty, it offers thought-provoking insights and exclusive interviews from experts in the field.

MashupMD is an innovative medical news and social media aggregator. The platform is optimized to deliver rapid access to the latest headlines in health care and collections of key medical content based on what health care professionals around the world are reading and sharing.

Cancer Nursing Today delivers critical news, research, and commentary to support oncology nurses throughout their education and careers. Its goal is to advance oncology treatments and care practices and promote the nurse’s role in enhanced patient outcomes and quality of life.

DocWire News is a leading source of medical industry news for health care professionals, featuring breaking news, expert commentary, research analysis, and conference highlights. It covers a comprehensive range of clinical specialties, including cardiology, oncology, neurology, and more.

Urban Health Today is the leading independent news source that provides urban health care professionals with relevant research and policy developments that impact patients and their practices. Its coverage focuses on clinical, social, and environmental health disparities.

Powered by DocWire News

GI Oncology Now is the leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies, offering the latest study data and research breakthroughs related to colorectal, gastric, liver, pancreatic, and esophageal cancers.

Heme Today produces the latest news and research for hematologists and oncologists focused on blood disorders such as clotting, red and white blood cell, and iron disorders, including conference highlights, late-breaking research, interviews with leaders in the field, and more.

A medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and data analysis to inform providers on the latest research and most effective clinical practices in the lung cancers space.

Nephrology Times delivers the latest news in nephrological treatments and technologies, curating content from clinical trials, conference highlights, and perspectives from key opinion leaders, with the goal of better informing care decisions and improving patient outcomes.

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |